Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Salima Hacein‐Bey‐Abina(Centre National de la Recherche Scientifique), Marina Cavazzana(Université Rennes 2), Adrian J. Thrasher(Great Ormond Street Hospital), Cécile Bouneaud, Frédérique Carlier, Alain Fischer(Inserm), Lilly Leiva, N. M. Wulffraat(Centre National de la Recherche Scientifique), Jean‐Pierre de Villartay(Université Paris Cité), Sophie Dupuis‐Girod(Hospices Civils de Lyon)
Cited by 1,050
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
|Science|2000|2.6k
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
|New England Journal of Medicine|2003|1.8k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k